This invention is related to chemistry and pharmacy and, in particular, to the production of novel molecular entities: tricyclic and tetracyclic derivatives of the benzodiazepine, pyridodiazepine, and pyrimidodiazepine type fused with 1,4-dihydropyridine derivatives, acting upon the Vascular and Central Nervous Systems. From derivatives containing a dihydropyridine ring reacting with compounds of the ortho -phenyldiamine, ortho -diaminopyridine, and ortho -diaminopyrimidine type, as well as some subsequent transformations thereof, tricyclic and tetracyclic derivatives of the I-XII general formula can be obtained, with a diazepine or diazepinone nucleus fused to a 1,4-dihydropyridine nucleus, wherein cycle A is a substituted or unsubstituted ring of benzene, pyridine or pyrimidine. Such molecular entities have a GABAergic and modulating action on calcium channels that can be used to treat cardiovascular, cerebrovascular, neurodegenerative, neuropsychiatric, and neurologic diseases.
